1. Home
  2. ADPT vs CASH Comparison

ADPT vs CASH Comparison

Compare ADPT & CASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$14.25

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Logo Pathward Financial Inc.

CASH

Pathward Financial Inc.

HOLD

Current Price

$86.89

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADPT
CASH
Founded
2009
1954
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.0B
IPO Year
2019
1996

Fundamental Metrics

Financial Performance
Metric
ADPT
CASH
Price
$14.25
$86.89
Analyst Decision
Strong Buy
Buy
Analyst Count
9
2
Target Price
$17.78
$107.50
AVG Volume (30 Days)
1.4M
178.2K
Earning Date
05-05-2026
04-22-2026
Dividend Yield
N/A
0.23%
EPS Growth
63.89
18.88
EPS
N/A
1.57
Revenue
$276,976,000.00
$839,894,000.00
Revenue This Year
$3.98
$7.56
Revenue Next Year
$22.72
$6.02
P/E Ratio
N/A
$55.43
Revenue Growth
54.77
11.29
52 Week Low
$8.38
$65.93
52 Week High
$20.76
$101.26

Technical Indicators

Market Signals
Indicator
ADPT
CASH
Relative Strength Index (RSI) 50.46 38.44
Support Level $12.22 $87.19
Resistance Level $15.38 $94.84
Average True Range (ATR) 0.62 3.18
MACD 0.02 -1.19
Stochastic Oscillator 50.26 17.83

Price Performance

Historical Comparison
ADPT
CASH

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

Share on Social Networks: